# BioHarvest Sciences Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/BioHarvest Sciences Inc).

## Overview

BioHarvest Sciences Inc. develops Botanical Synthesis technology for producing plant-based molecules and commercial ingredients. The company operates through a corporate group with roots in Israel and Canada, and its activities span research, manufacturing, and contract development and manufacturing relationships for specialty molecules and consumer ingredients.

## Products & services

• Botanical Synthesis platform for plant-based molecule production
• Contract development and manufacturing services (CDMO)
• Fragrance-related ingredient development programs
• Plant-based nutraceutical and specialty ingredient products
• Scale-up and production services through bioreactor-based manufacturing

- **Botanical Synthesis technology** (40%) — Core proprietary platform used to produce plant-based molecules and ingredients.
- **CDMO services** (25%) — Development and manufacturing services for partner companies and programs.
- **Fragrance ingredient programs** (20%) — Custom fragrance-related molecule development and supply programs.
- **Nutraceutical products** (15%) — Plant-based consumer and wellness ingredients sold through operating subsidiaries.

- Botanical Synthesis platform for plant-based molecule production
- Contract development and manufacturing services (CDMO)
- Fragrance-related ingredient development programs
- Plant-based nutraceutical and specialty ingredient products
- Scale-up and production services through bioreactor-based manufacturing

## Customers

BioHarvest sells to commercial partners that need specialty molecules, development support, or future supply capacity rather than broad mass-market consumers. The company also serves end-market buyers in premium fragrance and plant-based nutrition, where customers value scalable, sustainable ingredient production and technical differentiation.

- **Fragrance and scent houses** (primary) — Buy custom botanical molecules for premium fragrance programs and future supply agreements.
- **CDMO partners** (primary) — Use BioHarvest for development, scale-up, and manufacturing of specialty molecules.
- **Nutraceutical brands** (secondary) — Buy plant-based ingredients and products for wellness and consumer formulations.
- **Strategic commercial partners** (secondary) — Enter staged contracts to validate technology and support eventual commercialization.

- Fragrance and scent companies needing custom ingredient development
- Consumer brands seeking plant-based nutraceutical inputs
- Industrial partners outsourcing molecule development and manufacturing
- Investment-backed commercial partners for staged product programs
- Customers valuing scalable, sustainable botanical ingredients

## Geography

BioHarvest generates revenue in North America and Israel, with North America representing the larger share of recent reported revenue. The company is headquartered in Vancouver, maintains operations and subsidiaries in Israel, and also has access to European listing and investor markets through foreign trading venues.

- **North America** (87%)
- **Israel** (13%)

- North America is the largest reported revenue region
- Israel is a meaningful operating and revenue base
- Headquarters are in Vancouver, Canada
- Core development activity is tied to Israel-based operations
- Investor access extends to U.S. and European markets

## Strategy

BioHarvest’s strategy centers on scaling its Botanical Synthesis platform into repeatable commercial programs that can support partner-driven development and manufacturing. The company is also building toward royalty-driven economics by converting technical validation into longer-duration supply and commercialization relationships, particularly in premium fragrance and other specialty ingredient markets.

- **Commercialize fragrance molecule programs** (short-term) — Premium fragrance is a high-value end market that can validate the platform and generate repeat orders.
- **Scale manufacturing capacity** (medium-term) — Larger production capability is needed to support commercial supply and broader customer programs.
- **Win additional CDMO customers** (medium-term) — A broader customer base reduces concentration and improves platform utilization.

- Convert technical validation into commercial supply contracts
- Expand CDMO opportunities across multiple fragrance programs
- Increase manufacturing capacity through new production assets
- Build royalty-driven income from platform-enabled products
- Use partner programs to prove scalability and attract new customers

## Risks

BioHarvest depends on successful technology scale-up, customer conversion, and timely facility expansion to turn development programs into durable revenue. It also faces execution risk typical of specialty biotech/manufacturing models, including customer concentration, development delays, and the possibility that commercial demand for novel ingredients develops more slowly than planned.

- **Technology scale-up failure** [high] — The business must move from development success to repeatable production at commercial scale.
- **Customer and program concentration** [high] — Revenue can depend on a limited number of contracts and development milestones.
- **Manufacturing capacity timing** [medium] — Commercial supply depends on new facility commissioning and production readiness.
- **Market adoption risk** [medium] — Novel plant-based molecules must gain traction against established sourcing methods.

- Commercialization depends on successful scale-up and production readiness
- New customer conversion may take time in specialty ingredient markets
- Single-program delays can push back revenue and manufacturing utilization
- Customer concentration can make results volatile quarter to quarter
- Biotech and manufacturing scale-up carry technical and regulatory risk

## Accounting

Revenue appears to be driven by specific customer programs and geography-based sales, so timing of milestone acceptance and shipment/service completion can affect period-to-period comparability. The company also has meaningful judgment areas around inventory, property and equipment for scale-up assets, and right-of-use assets from leased facilities, while development-stage spending and government support can influence reported results.

- **Revenue recognition for customer programs** — Affects quarterly comparability and reported growth
- **Inventory and production assets** — Can affect gross margin and asset carrying values
- **Lease accounting** — Affects EBITDA-like measures and balance sheet leverage
- **Government grants** — Can materially offset reported R&D spending

- Program-based revenue timing may depend on contract stage completion
- Revenue can fluctuate with customer milestones and commercialization timing
- Inventory valuation matters for bioproducts and scale-up materials
- Capitalized production assets and leases affect depreciation and rent expense
- R&D support and government grants can offset development spend

---

*Last updated: 2026-09-28T11:57:48.683525+00:00*